Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a unknown/unknown for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist that reduces nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: Helps ​the ​patient ​experience ​fewer ​episodes ​of ​vomiting ​and ​less ​nausea ​during ​cancer ​treatment. - Post‑operative ​post‑operative ​nausea and vomiting (PONV): ​Provides ​pro‑ ​phylactic ​pro‑​treatment ​against ​vom ​ ​. - Radiotherapy ​radiotherapy ​induced ​nausea ​and ​vomiting ​(RINV). ​Red ​uces ​the ​severity ​of ​symptoms ​.

Common   t